A
Alcista
Alcista · 25%IMVT
$16.79
Precio del escenario
$27.510
-0.385 (-1.40%)Al cierre
Loading chart…
- Máximo
- 28.330
- Apertura
- 28.030
- Precio medio ponderado por volumen
- 27.77
- Volumen
- 1.65M
- Capitalización
- 3.80B
- Mínimo
- 27.475
- Importe
- 45.80M
- EV/EBITDA, TTM
- 0.00
Immunovant, Inc. is a clinical-stage immunology company enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The Company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).
Análisis de IA of Immunovant Inc (IMVT)
MantenerImmunovant Inc is not a good buy right now due to significant recent setbacks in drug development and declining investor sentiment. The current price is $30.47, down 9.37% over the last five days, and the RSI is at a low 12.81, indicating oversold conditions. The main risk is the halted development of IMVT-1402, which has created uncertainty in the company's future prospects.
Métricas de valoración
El PER previsto actual de Immunovant Inc (IMVT) es 0.00, frente a su media de 5 años de -9.03.
Escenarios de precio de Alphio AI para IMVT
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con IMVT en cartera
Cronología de eventos
Noticias
7.010-12PRnewswireKuehn Law Investigates Immunovant Executives for Fiduciary Breaches
7.010-11NewsfilterSBS Investigates Immunovant for Securities Violations
5.010-08stocktwitsIMVT-1402 Study Failure Triggers Market Reaction
7.009-25PRnewswireImmunovant Stock Drops 6% After Study Misses Primary Endpoint
2.009-23CNBCMcDonald's CEO Warns of Inflation Impact on Sales
Preguntas frecuentes sobre IMVT, respondidas por Alphio AI
Immunovant, Inc. is a clinical-stage immunology company enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The Company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Immunovant Inc is not a good buy right now due to significant recent setbacks in drug development and declining investor sentiment. The current price is $30.47, down 9.37% over the last five days, and the RSI is at a low 12.81, indicating oversold conditions. The main risk is the halted development of IMVT-1402, which has created uncertainty in the company's future prospects.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.